Partner With Us
Position Your Brand at the Forefront of T-Cell Engager Innovation in Autoimmunity
The T-Cell Engager for Autoimmune Disease Summit is the first and only industry-dedicated meeting bringing together global biopharma leaders to accelerate the development of safer, more precise, and more scalable T-cell engager (TCE) therapies for autoimmune indications such as lupus, rheumatoid arthritis, and beyond.
With C-suite executives, R&D leaders, and translational scientists actively seeking partners who can support TCE design, characterization, and development outside oncology, now is the time to position your solutions in front of the right audience.
Whether you're offering protein engineering technologies, preclinical CRO services, immune safety profiling tools, or biomarker discovery platforms, this summit provides direct access to decision-makers focused on:
Reducing CRS and systemic toxicities
Expanding autoimmune-relevant targets beyond B cells
Improving translation from preclinical models to clinical success
Differentiating TCEs from standard-of-care biologics in inflammatory diseases
Why Partner with the T-Cell Engager for Autoimmune Disease Summit?

Showcase Your Technical Expertise
Demonstrate how your antibody or TCE-supporting platform addresses key challenges in autoimmune drug development, such as reducing immunotoxicity, boosting tissue selectivity, or refining target engagement.

Generate Qualified Leads Across Biotech & Pharma
Meet C-level, VP, and director-level stakeholders actively sourcing tools and collaborators for autoimmune-focused TCE discovery and development.

Highlight Your Role in Translational Advancement
Position your preclinical models, translational platforms, or bioanalytical services as essential for improving clinical safety and efficacy readouts in emerging autoimmune trials.

Shape Strategic Collaborations in a Rapidly Emerging Field
Be part of the conversations defining how TCEs will evolve in autoimmunity and partner with the innovators leading the charge beyond oncology.